MBS498 - How to solve endometriosis problems for 190 million women - Somer Baburek, CEO Herabiotech (Built in Texas #3)
Matt Brown Show - Telling the stories of influencers and business thought leaders, one conversation at a time
English - October 26, 2022 22:00 - 53 minutes - 36.8 MB - ★★★★ - 4 ratingsBusiness business entrepreneurships technology authors startups business news crypto Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Hera began operations in January of 2020 as a Delaware “C” Corporation with headquarters in San Antonio, TX. Hera’s initial goal is to commercialize the MetriDx™, a novel, non-surgical method for the definitive and early diagnosis of endometriosis. Endometriosis is defined as the presence of endometrial glands and stromal-like lesions outside of the uterus.
Endometriosis affects 10-20% of all women of reproductive age; 7-13 million in the US alone. Current diagnosis of endometriosis is by visualization during laparoscopic surgery, confirmed by histological pathology, performed under general anesthesia by a surgeon or gynecologist.
The surgical methodology suffers from being highly site specific, depending on the experience of the surgeon, failure to detect lesions in ~16% of cases and almost half of all biopsies are negative.
Alternatively, many physicians choose to diagnose the disease empirically or, without a definitive diagnosis; this results in multiple “trial & error” interventions, increased liability risk and patient frustration. In most cases, patients suffer between 7-12 years with intense pain before a diagnosis is given and interventions are administered, with 68% of women with endometriosis being misdiagnosed with another condition prior to receiving the correct diagnosis.
Get interviewed on the Matt Brown Show: www.mattbrownshow.com